Content area

Abstract

Many Src Homology 3 (SH3) domains function as molecular adhesives in intracellular signal transduction. Based on previous ultrastructural studies, short motifs which bind to the first SH3 domains of the adapters Crk and CRKL were selectively mutagenised to generate Crk/CRKL SH3-binding peptides of very high affinity and selectivity. Affinities were increased up to 20-fold compared to the best wildtype sequences, while the selectivity against a similar SH3 domain [Grb2SH3(N)] was not only retained, but sometimes increased. Blot techniques with GST-fusion peptides and in solution precipitation assays with biotinylated high affinity Crk binding peptides (HACBPs) were subsequently used to analyse the binding of these sequences to a large panel of SH3 domain-containing fusion proteins. Only those proteins which contained the CrkSH3(1) or CRKLSH3(1) domains bound efficiently to the HACBPs. A GST-HACBP fusion protein precipitated Crk and CRKL proteins out of 35S-labelled and unlabelled cell lysates. Very little binding of other cellular proteins to HACBP was detectable, indicative of a great preference for Crk and CRKL when compared to the wide variety of other endogenous cellular proteins. Moreover, HACBP disrupted in vitro preexisting Crk-complexes with DOCK180 and the exchange factors SoS and C3G, which are known targets of Crk adapters, in a concentration dependent manner. HACBP-based molecules should therefore be useful as highly selective inhibitors of intracellular signalling processes involving Crk and CRKL.

Details

Title
Development of highly selective SH3 binding peptides for Crk and CRKL which disrupt Crk-complexes with DOCK180, SoS and C3G
Author
Posern Guido 1 ; Zheng, Jie 2 ; Knudsen, Beatrice S 3 ; Kardinal, Christian 1 ; Müller, Kerstin B 1 ; Voss, Jan 1 ; Shishido Tomoyuki 3 ; Cowburn, David 2 ; Cheng Genhong 4 ; Wang, Baolin 5 ; Kruh, Gary D 6 ; Burrell, Sarah K 7 ; Jacobson, Christina A 7 ; Lenz, Douglas M 7 ; Zamborelli, Thomas J 7 ; Adermann Knut 8 ; Hanafusa Hidesaburo 3 ; Feller, Stephan M 1 

 Laboratory of Molecular Oncology, Institute for Medical Radiation and Cell Research (MSZ), Bavarian Julius-Maximilians University, Würzburg, Germany (GRID:grid.8379.5) (ISNI:0000 0001 1958 8658) 
 Laboratory of Physical Biochemistry, Rockefeller University, New York, USA (GRID:grid.134907.8) (ISNI:0000 0001 2166 1519) 
 Laboratory of Molecular Oncology, Rockefeller University, New York, USA (GRID:grid.134907.8) (ISNI:0000 0001 2166 1519) 
 Massachusetts Institute of Technology, Cambridge, USA (GRID:grid.116068.8) (ISNI:0000 0001 2341 2786); Jonsson Comprehensive Cancer Center, University of California Los Angeles School of Medicine, Los Angeles, (GRID:grid.19006.3e) (ISNI:0000 0000 9632 6718) 
 University of Pennsylvania, Department of Biology, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972); Fox Chase Cancer Center, Department of Medical Oncology, Philadelphia, USA (GRID:grid.412530.1) (ISNI:0000 0004 0456 6466) 
 Fox Chase Cancer Center, Department of Medical Oncology, Philadelphia, USA (GRID:grid.412530.1) (ISNI:0000 0004 0456 6466) 
 AMGEN Boulder Inc., Peptide Technology Group, Boulder, USA (GRID:grid.412530.1) 
 Lower Saxony Institute for Peptide Research (IPF), Hannover, Germany (GRID:grid.412530.1) 
Pages
1903-1912
Publication year
1998
Publication date
Apr 1998
Publisher
Nature Publishing Group
ISSN
09509232
e-ISSN
14765594
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2641293057
Copyright
© Macmillan Publishers Limited 1998.